HCW Biologics (HCWB) shares were sharply higher in Monday's premarket session after it said it received US Food and Drug Administration clearance to launch a phase 1 trial to evaluate HCW9302 for the treatment of moderate-to-severe alopecia areata.
The company said the goal of the trial is to determine a safe dose of HCW9302 that effectively increases regulatory T cell activity in patients.
"Once we achieve this objective, we will rapidly expand clinical development of HCW9302 in phase 2 studies in patients with other autoimmune diseases and inflammatory conditions," Chief Executive Hing Wong said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.